These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 16614006)

  • 1. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
    Pirson L; Baron F; Meuris N; Giet O; Castermans E; Greimers R; Di Stefano I; Gothot A; Beguin Y
    Stem Cells; 2006 Jul; 24(7):1814-21. PubMed ID: 16614006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells.
    Belle L; Bruck F; Foguenne J; Gothot A; Beguin Y; Baron F; Briquet A
    PLoS One; 2012; 7(12):e52564. PubMed ID: 23285088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The alpha4beta1 and alpha5beta1 integrins mediate engraftment of granulocyte-colony-stimulating factor-mobilized human hematopoietic progenitor cells.
    Carstanjen D; Gross A; Kosova N; Fichtner I; Salama A
    Transfusion; 2005 Jul; 45(7):1192-200. PubMed ID: 15987366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of imatinib on bone marrow engraftment in syngeneic mice.
    Hoepfl J; Miething C; Grundler R; Götze KS; Peschel C; Duyster J
    Leukemia; 2002 Sep; 16(9):1584-8. PubMed ID: 12200667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
    Kuroda J; Kimura S; Segawa H; Kobayashi Y; Yoshikawa T; Urasaki Y; Ueda T; Enjo F; Tokuda H; Ottmann OG; Maekawa T
    Blood; 2003 Sep; 102(6):2229-35. PubMed ID: 12763930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The late dividing population of gamma-retroviral vector transduced human mobilized peripheral blood progenitor cells contributes most to gene-marked cell engraftment in nonobese diabetic/severe combined immunodeficient mice.
    Brenner S; Ryser MF; Whiting-Theobald NL; Gentsch M; Linton GF; Malech HL
    Stem Cells; 2007 Jul; 25(7):1807-13. PubMed ID: 17464090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High CD133 expression levels in gastrointestinal stromal tumors.
    Bozzi F; Conca E; Manenti G; Negri T; Brich S; Gronchi A; Pierotti MA; Tamborini E; Pilotti S
    Cytometry B Clin Cytom; 2011; 80(4):238-47. PubMed ID: 21462307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of imatinib on normal progenitor cells in vitro.
    Bartolovic K; Balabanov S; Hartmann U; Komor M; Boehmler AM; Bühring HJ; Möhle R; Hoelzer D; Kanz L; Hofmann WK; Brümmendorf TH
    Blood; 2004 Jan; 103(2):523-9. PubMed ID: 12969987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
    Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.
    Vianello F; Villanova F; Tisato V; Lymperi S; Ho KK; Gomes AR; Marin D; Bonnet D; Apperley J; Lam EW; Dazzi F
    Haematologica; 2010 Jul; 95(7):1081-9. PubMed ID: 20179085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human CD133-positive hematopoietic progenitor cells initiate growth and metastasis of colorectal cancer cells.
    Zhang C; Zhou C; Wu XJ; Yang M; Yang ZH; Xiong HZ; Zhou CP; Lu YX; Li Y; Li XN
    Carcinogenesis; 2014 Dec; 35(12):2771-7. PubMed ID: 25269803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
    Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
    Appel S; Boehmler AM; Grünebach F; Müller MR; Rupf A; Weck MM; Hartmann U; Reichardt VL; Kanz L; Brümmendorf TH; Brossart P
    Blood; 2004 Jan; 103(2):538-44. PubMed ID: 14504105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo culture of human cord blood hematopoietic stem/progenitor cells adversely influences their distribution to other bone marrow compartments after intra-bone marrow transplantation.
    Yamamura K; Ohishi K; Masuya M; Miyata E; Sugimoto Y; Nakamura S; Fujieda A; Araki H; Katayama N
    Stem Cells; 2008 Feb; 26(2):543-9. PubMed ID: 17975223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
    O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
    J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
    Shinagawa K; Kitadai Y; Tanaka M; Sumida T; Onoyama M; Ohnishi M; Ohara E; Higashi Y; Tanaka S; Yasui W; Chayama K
    Int J Cancer; 2013 Feb; 132(4):813-23. PubMed ID: 22821812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
    Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U
    Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.